

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
February 9, 2023

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Rhea Bhatt

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Mark Conaway, PhD

Professor and Director of Translational Research
Division of Translational Research and Applied
Statistics
Department of Public Health Sciences
University of Virginia
Charlottesville, Virginia

Jorge A. Garcia, MD, FACP

(Chairperson)
Chief, Division of Solid Tumor Oncology
George and Edith Richman Distinguished Scientist
Chair
Professor of Medicine and Urology
GU Medical Oncology Program
University Hospitals Seidman Cancer Center
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland, Ohio

Pamela L. Kunz, MD

Associate Professor of Medicine (Oncology)
Division Chief, GI Oncology
Vice Chief
Diversity Equity and Inclusion, Medical Oncology
Yale School of Medicine and Yale Cancer Center
New Haven, Connecticut

Christopher H. Lieu, MD

Associate Professor of Medicine
Associate Director for Clinical Research
co-Director, Gastrointestinal Medical Oncology
University of Colorado Cancer Center
Aurora, Colorado

Ravi A. Madan, MD

Senior Clinician, Genitourinary Malignancies Branch
Head, Prostate Cancer Clinical Research Section
Program Director, Physician-Scientist Early
Investigator Program
Center for Cancer Research
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

David E. Mitchell

(Consumer Representative)
Founder, Patients for Affordable Drugs
Bethesda, Maryland

Jorge J. Nieva, MD

Associate Professor of Clinical Medicine
Section Head, Solid Tumors
University of Southern California (USC) Norris
Comprehensive Cancer Center
Keck School of Medicine of USC
Los Angeles, California

Neil Vasan, MD, PhD

Assistant Professor of Medicine
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
February 9, 2023

MEETING ROSTER (cont.)

ACTING INDUSTRY REPRESENTATIVE TO THE COMMITTEE (Non-Voting)

Albert L. Kraus, PhD

(Acting Industry Representative)

Global Regulatory Portfolio Lead – Oncology
Pfizer, Inc.
Guilford, Connecticut

TEMPORARY MEMBERS (Voting)

George J. Chang, MD, MS

Professor and Chair ad interim
Department of Colon and Rectal Surgery
Sue and Radcliffe Killam Chair
Associate Vice President, Regional Surgery
Strategy
The University of Texas, MD Anderson Cancer
Center
Houston, Texas

Kristen K. Ciombor, MD, MSCI

Associate Professor of Medicine
Department of Internal Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Evangelia Katsoulakis, MD

Veterans Affairs (VA) Hospital
Department of Radiation Oncology and Clinical
Informatics
Associate Professor Radiation Oncology
University of South Florida
Tampa, Florida

Paul V. Majkowski, Esq.

(Patient Representative)
Albertson, New York

John H. Park, MD

Staff Physician
Department of Radiation Oncology
Kansas City VA Medical Center
Clinical Assistant Professor
University of Missouri Kansas City
Kansas City, Missouri

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
February 9, 2023

MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director, Oncology Center of Excellence (OCE)
Director (Acting)
Office of Oncologic Diseases (OOD)
Office of New Drugs (OND), CDER, FDA

Paul Kluetz, MD

Deputy Center Director, OCE
Supervisory Associate Director (Acting)
OOD, OND, CDER, FDA

Steven Lemery, MD, MHS

Director
Division of Oncology Products 3 (DO3)
OOD, OND, CDER, FDA

Lola Fashoyin-Aje, MD, MPH

Deputy Director
DO3, OOD, OND, CDER, FDA

Sandra Casak, MD

Clinical Team Leader
Gastrointestinal Cancers Team
DO3, OOD, OND, CDER, FDA